Rafael Holdings, Inc. (RFL): R&D Expense
$24.33M
Year ended 2026-07-31
+56.8%
3-year compound annual growth
+37.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2026-07-31 | $24.33M | +89.8% | 2026-10-29, From 2025-08-01 |
| 2025-07-31 | $12.82M | +207.5% | 2026-10-29, From 2024-08-01 |
| 2024-07-31 | $4.17M | -33.9% | 2025-10-29, From 2023-08-01 |
| 2023-07-31 | $6.31M | -27.8% | 2024-12-20, From 2022-08-01 |
| 2022-07-31 | $8.74M | +78.2% | 2023-10-30, From 2021-08-01 |
| 2021-07-31 | $4.91M | +105.2% | 2022-10-31, From 2020-08-01 |
| 2020-07-31 | $2.39M | +132.8% | 2021-10-18, From 2019-08-01 |
| 2019-07-31 | $1.03M | +3.2% | 2020-10-29, From 2018-08-01 |
| 2018-07-31 | $995.0K | n/a | 2019-10-04, From 2017-08-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | 2026-07-31 | $24.33M | +89.8% |
| Rallybio Corp (RLYB) | 2025-12-31 | $19.60M | -52.8% |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $35.27M | -47.5% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $2.11M | -57.8% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $5.52M | -61.4% |
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $8.24M | +249.0% |
| Neuphoria Therapeutics Inc. (NEUP) | 2025-06-30 | $9.01M | -4.4% |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $30.25M | -0.6% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $12.04M | +48.0% |
Compare RFL, RLYB, STTK, SXTP side by side · Screen every company in Pharmaceutical Preparations ↗